Zheng Quan Shi Bao Wang·2025-07-30 08:41Group 1 - The core viewpoint of the news is that the Artemisinin concept sector has shown a positive performance, with a 2.33% increase, ranking second among concept sectors on the trading day [1][2] - Within the Artemisinin concept sector, eight stocks experienced gains, with notable increases from China Resources Double Crane (6.42%), Zhejiang Medicine (6.14%), and Fosun Pharma (4.19%) [1][2] - Conversely, the sector also saw declines in stocks such as Haizheng Pharmaceutical and Delong Huineng, which fell by 1.84% and 0.16% respectively [1][2] Group 2 - The financial inflow for the Artemisinin concept sector was significant, with a net inflow of 409 million yuan, indicating strong interest from major investors [2][3] - Fosun Pharma led the net inflow with 153 million yuan, followed by China Resources Double Crane (144 million yuan) and Zhejiang Medicine (86.87 million yuan) [2][3] - The top stocks by net inflow ratio included New Hualian (6.78%), China Resources Double Crane (6.54%), and Zhejiang Medicine (5.97%) [3]